Scil Proteins Gmbh

Biontech Se

Biontech Ag

Jpt Peptide Technologies Gmbh

Ganymed Pharmaceuticals Ag

Universitätsmedizin Der Johannes Gutenberg-universitat Mainz

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz Ggmbh

Ganymed Pharmaceuticals Gmbh

Tron Ggmbh

Celares Gmbh

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Guttenberg-universitat Mainz Gemeinnuizige Gmbh

Tron—translationale Onkologic an Der Universitätsmedzin Der Johannes Gutenberg-universität Mainz Gemcinnützige Gmbh

Astellas Pharma Gmbh

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Navigo Proteins Gmbh

Markus Fiedler

Ugur Sahin

Ulrike Fiedler

Hans-Ulrich Schmoldt

Matin Daneschdar

Erik Fiedler

Arnd Steuernagel

Ulf Reimer

Arne Jendretzki

Julia Holland

Hayat Bähr-Mahmud

Joycelyn Wüstehube-Lausch

Anja Kunert

Ozlem Tureci

Özlem Türeci

Rainer Rudolph

Tim Beissert

Fabrice Le Gall

Christiane Regina Stadler

Karsten Schnatbaum

Laura Plum

Joerg Nerkamp

Eva Bosse-Doenecke

Thomas Hey

Ozlem Türeci

Frank Leenders

Ralf Kraehmer

Manja Gloser

Bonny Gaby Lui

Laura Marie Kring

Nadja Salomon

Thomas Goettler

Ilka Haenssgen

Jörg Narkamp

Laura-Marie Kring (née Plum)

Thomas Göttler

Laura-Marie Plum

Ilka Haenßgen

Jörg Nerkamp

The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

Compositions and methods for diagnosis and treatment of cancer

The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3&#x3b5;). These molecules compete with CD3&#x3b5; for binding to a CD3&#x3b5; binding domain. e.g. a CD3&#x3b5; binding domain of an antibody, and are capable of detecting antibodies against CD3&#x3b5;. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3&#x3b5; antibody purification and the detection of anti-CD3&#x3b5; antibodies in biological samples.

Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Peptide mimotopes of claudin 18.2 and uses thereof

The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Agents for treatment of claudin expressing cancer diseases

The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.

The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.

Dimeric binding proteins based on modified ubiquitins

The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.

Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin

The invention relates to modified proteins of the superfamily of 'ubiquitin-like proteins', proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.

Artificial binding proteins based on ubiquitin

Generation of artificial binding proteins on the basis of ubiquitin proteins

The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided.

Method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands

The present invention is directed to a multimeric agent and a multimeric conjugate formed from this multimeric agent and a biologically active agent. Said multimeric conjugates have a longer life time in vivo and an increased avidity compared to the unmodified biologically agent. The present invention is further directed to a pharmaceutical or diagnostic composition containing said conjugate as well as to a method of its production. The invention additionally provides the use of said conjugates for the detection, determination, separation and/or isolation of a specific binding partner and for the diagnosis, prophylaxis and treatment of diseases in which the specific binding partner is directly or indirectly involved.

Multimeric conjugate

Growing community of inventors

Halle an der Saale, Germany

Markus Fiedler